| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.2 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.24 | 0.2 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.072 | 0.2 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |